Asia Pharma R&D Leaders Summit 2017
March. 21 ( Tuesday ) to March 22 ( Wednesday ), 2017
Agenda
VISONARY KEYNOTE SESSIONS

Speeding Innovation in Pharma: The Global Partnering Imperative
Uwe Schoenbeck, Senior Vice President, Chief Scientific Officer, External R&D Innovation (ERDI), Pfizer Worldwide R&D

Discovery and evaluation of peptides & proteins for the treatment of type 2 diabetes
Abstract: The presentation will cover the unmet needs of type 2 diabetes as well as Novo Nordisk’s approach to evaluation of new targets from the public domain.
Soren Tullin,Corporate Vice President for Discovery Biology and Technology, Novo Nordisk

Open Innovation in University-Industrial Partnership for BioMedical Technology Development
Dongmin Chen,Dean, School of Innovation and Entrepreneurship | Director, Office of Science & Technology Development, Peking University

Challenges of Conducting Clinical Trials in APAC for Pharma and Med Device
-- Drivers of trend for CT in APAC
-- Mistakes made by Pharma in Emerging Markets
-- Complex regulatory environment for Pharma and Med Device
-- Regulatory Requirements & IRB approval Process in Asia
Timothy Low, Chief Executive Officer, Executive Office, FARRER PARK HOSPITAL

Academia-industry collaboration: regional opportunities with global outlook
Min Li, SVP, Global Head of Neuroscience Therapy Area and General Manager, GSK R&D Center China

Singapore’s A*STAR: The role of Research and Technology Organisations in Open Innovation
Abstract: This presentation will describe how public sector R&D investments, and in particular, how organisations like A*STAR or the Agency for Science, Technology and Research, have played a crucial role in developing the research ecosystem in Singapore, and in providing a link between academic research and economic value capture for the country. It will further highlight how A*STAR’s approach to open innovation has resulted in successful partnerships with both multinational and local companies, and contributed towards improving health outcomes.
BENJAMIN SEET, Executive Director, Biomedical Research Council, Agency for Science, Technology and Research, Singapore

Bringing excellence in science to China --- Surfing the 13.5 Innovation Wave from MNC perspectives
Bin Jerica Shi , Head of External R&D and Licensing, Amgen Asia R&D Center

Translational models of diabetes and complications in rodents and nonhuman primates: applications in pharmaceutical research
Jim Wang, SENIOR VP CARDIOVASCULAR AND METABOLIC DISEASES (CVMD) RESEARCH, CrownBio

USP Mission: Improving public health through public standards and related programs
The presentation will discuss USP’s legacy since 1820, its growing impact in public health, especially in the pharmaceutical industry. It will cover USP’s strategic initiatives to update about 1,700 monographs by 2020, its expanding outreach worldwide, and USP-China’s role in the global efforts
Bingbing Feng, Vice President and General Manager, USP-China

Gastric bypass surgery for T2D treatment
Wu Jia-Rui, Professor, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences

Accelerating Drug Discovery through A Fully Integrated Testing Platform
Jason Liu, Senior Vice President, Chief Operating Officer for Lab Testing Division, WuXi AppTec

Working Together for Better Health- Partnering with Boehringer Ingelheim
The current R&D Strategy of Boehringer Ingelheim will foster the external collaboration efforts and will enable BI to be more competitive and more flexible. With the newly established research organization of Research Beyond Borders ( RBB ). BI is able to explore emerging science, new indication and new technology to expand opportunities via partnering with external collaborators. RBB complements the company’s five core therapeutic areas ( cardiometabolic, respiratory, immunology, oncology and central nervous system ) by exploring emerging science, disease areas and technology. It will contribute new innovation opportunities within and beyond the core therapeutic areas and ensure early entry for Boehringer Ingelheim in the next big innovation waves in biomedical research. Boehringer Ingelheim is expanding its activities in Asia and looking for more partnering opportunities. By combing a focus on cutting-edge science with a long-term view the company aspires to develop the next generation of medical breakthroughs to improve the lives of patients with high unmet medical needs.
Henri Doods, Vice President Global Department Research Beyond Borders, Boehringer Ingelheim

INTERACTIVE ROUNDTABLE DISCUSSIONS

R&D Leaders Roundtable: R&D Innovation & Partnership in China – Next Five Years and Beyond
Abstract: This featured R&D Leaders roundtable discussion will explore the evolving future of innovative R&D in China: We have invited the leaders in Global/Regional R&D Executives to share their vision and experience in promoting drug discover innovation in Asia

Moderator:
Tobias Gabriel, Head of External Science & Drug Discovery, Global Discovery Chemistry,Novartis Institutes for BioMedical Research (NIBR)

Panelists:
Uwe Schoenbeck, SVP, Chief Scientific Officer, External R&D Innovation & CTI, WRD, Pfizer
Joern-Peter Halle, SVP, Head of External Innovation, Merck Serono
Tom Kinzel, Head of Drug Discovery -- Innovation Centre China, Pharmaceutical Division,Bayer
Benjamin Seet, Executive Director, Biomedical Research Council, Agency for Science, Technology and Research, Singapore
Mike Dethick, Managing Director, R&D-Based Pharmaceutical Association Committee
Min Li, Senior Vice President, Global Head of Neuroscience Therapy Area and General Manager, GSK R&D Center China
Dongmin Chen,Dean, School of Innovation and Entrepreneurship | Director, Office of Science & Technology Development, Peking University

Promoting China Innovation: Developing the Strategic and Innovative Partnership in China.

Panelists:
Binhui (Ben) Ni, AVP, Head, External Innovation & Partnering Strategy and Business Development, Asia Pacific, Sanofi
Tom Kinzel, Head of Drug Discovery, Innovation Centre China, Pharmaceuticals Division, Bayer
Mu Hua, CSO and President of R&D, Simcere Pharmaceutical Group
Bin Li, Director, Search and Evaluation JAPAC, Abbvie China
Bin Shi, Head of External R&D and Licensing, Amgen Asian R&D Center
Dong Wu, Head, Johnson & Johnson Innovation Asia Pacific Innovation Center

Novo Nordisk T2D Workshop

Topic: Future Type 2 Diabetes (T2D) treatment: where to go and how to get there?

LEARNING OBJECTIVES
-- What is the future trend for T2D treatment?
-- What is the biology or drug target that may lead to the future T2D treatment?
-- What technology may lead to the future T2D treatment?

Supaglutide: Novel GLP-1 receptor agonist, its efficacy, potency, post-receptor mechanisms and potential clinical application.
-- Recent advances in GLP-1 biology and incretin-based therapies
-- Regulation of GLP-1 on glucose and energy homeostasis: insulinotropic and insulinomimetic actions
-- Current GLP-1 therapy strategies: half-life, dossing and efficacy
-- Supaglutide: rationale of design, manufacturing and control, and preclinical studies
-- Expectation: clinical outcomes and perspective in treating type 2 diabetes and metabolic disorders

GPCR and me: 15 years' scientific efforts in Shanghai
-- Brief history of the research activities on G-protein coupled receptors (GPCRs) in Shanghai between 2002 and 2016
-- Persistent efforts made in the discovery of small molecule modulators of glucagon-like peptide-1 receptor (GLP-1R)
-- Chemical biology guided studies on the structures and functions of class B GPCRs important to type 2 diabetes

Asia Pharma R&D Leaders Summit 2017  |  Telephone: +86 21 6172 6970  |  E-mail: kevin.tan@deliver-consulting.com
© 2016 Asia Pharma R&D Leaders Summit 2017- All rights reserved